Cytosorbents (CTSO) Share-based Compensation (2010 - 2026)

Cytosorbents has reported Share-based Compensation for 17 years, with the latest figure at $544000.0 in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 33.5% year-over-year to $544000.0; the trailing twelve-month figure through Mar 2026 stood at $2.5 million (down 31.21% YoY), and the FY2025 full-year result was $2.8 million, down 26.46% from the prior year.
• Share-based Compensation for Q1 2026 stood at $544000.0, down from $886000.0 in the prior quarter.
• The five-year high for Share-based Compensation was $1.7 million in Q4 2023, with the low at $488000.0 in Q3 2025.
• Historically, Share-based Compensation has averaged $861396.5 across 5 years, with a median of $869517.0 in 2022.
• Annual changes were most pronounced in 2022 — Share-based Compensation slumped 51.16% — and 2023, when it soared 91.87%.
• Cytosorbents' Share-based Compensation stood at $869517.0 in 2022, then soared by 91.87% to $1.7 million in 2023, then slumped by 44.86% to $920000.0 in 2024, then decreased by 3.7% to $886000.0 in 2025, then tumbled by 38.6% to $544000.0 in 2026.
• The last three Share-based Compensation figures came in at $544000.0 (Q1 2026), $886000.0 (Q4 2025), and $488000.0 (Q3 2025), per Business Quant data.